Citations

Clear

27 citation(s) found for "Suleiman, L".

Advancing head and neck cancer management: Unveiling the diagnostic and therapeutic potentials of molecular profiling
Baral, Binav, Suleiman, Riham , Fazer-Posorske, Casey , Thomé, Stephan D. , Molina, Julian R. , Price, Katharine A., Halfdanarson, Thorvardur R., Fazer-Posorske, Casey A, McGarrah, Patrick W. , Daniel, J. , Hálfdánarson, Þorvarður R. , Fuentes, Harry E

Mayo Clinic

Head & Neck | July 20, 2024 | Volume: 46 | Issue: 10 | Pages: No page available

10.1002/hed.27882 | PMID 39032143 Get It

AbstractBackgroundHead and neck cancers (HNC) present diagnostic challenges due to multifocal disease manifestations, posing difficulties in distinguishing between metastatic disease and second primary malignancies (SPM). This complexity underscores the need for advanced diagnostic approaches. Emerging technologies, such as next‐generation sequencing (NGS) and molecular classifier assays, show promise in providing precise insights into the diverse etiologies of HNC.MethodIn this article, we employed NGS and molecular classifier assays to delve into three distinct clinical cases. The objective was to showcase the instrumental role of these technologies in facilitating accurate diagnoses and differentiating between metastatic disease and SPM in HNC cases.ResultsThe results of this series highlight the effectiveness of NGS and molecular classifier assays in enhancing diagnostic accuracy for HNC and contributing to the precise differentiation of disease etiologies. The utilization of these advanced technologies proved instrumental in avoiding unnecessary interventions and paved the way for more targeted and effective treatment strategies.ConclusionOur findings underscore the necessity of incorporating advanced molecular testing technologies into the diagnostic and therapeutic approaches for HNC, thereby championing a more nuanced and effective approach to managing these complex cases.
Identification of ChatGPT‐Generated Abstracts Within Shoulder and Elbow Surgery Poses a Challenge for Reviewers
Stadler, Ryan D. , Sudah, Suleiman Y. , Denard, Patrick J. , Duralde, Xavier A. , Garrigues, Grant E. , Klifto, Christopher S. , Namdari, Surena , Sánchez‐Sotelo, Joaquín , Menendez, Mariano E. , Sanchez-Sotelo, Joaquin, Sanchez-Sotelo, J. , Denard, Patrick J , Moverman, Michael A. , Levy, Jonathan C., Menendez, Mariano E.

Mayo Clinic

Arthroscopy | July 9, 2024 | Volume: 41 | Issue: 4 | Pages: 916

10.1016/j.arthro.2024.06.045 | PMID 38992513 Get It

Purpose To evaluate the extent to which experienced reviewers can accurately discern between artificial intelligence (AI)–generated and original research abstracts published in the field of shoulder and elbow surgery and compare this with the performance of an AI detection tool. Methods Twenty‐five shoulder‐ and elbow‐related articles published in high‐impact journals in 2023 were randomly selected. ChatGPT was prompted with only the abstract title to create an AI‐generated version of each abstract. The resulting 50 abstracts were randomly distributed to and evaluated by 8 blinded peer reviewers with at least 5 years of experience. Reviewers were tasked with distinguishing between original and AI‐generated text. A Likert scale assessed reviewer confidence for each interpretation, and the primary reason guiding assessment of generated text was collected. AI output detector (0%‐100%) and plagiarism (0%‐100%) scores were evaluated using GPTZero. Results Reviewers correctly identified 62% of AI‐generated abstracts and misclassified 38% of original abstracts as being AI generated. GPTZero reported a significantly higher probability of AI output among generated abstracts (median, 56%; interquartile range [IQR], 51%‐77%) compared with original abstracts (median, 10%; IQR, 4%‐37%; P < .01). Generated abstracts scored significantly lower on the plagiarism detector (median, 7%; IQR, 5%‐14%) relative to original abstracts (median, 82%; IQR, 72%‐92%; P < .01). Correct identification of AI‐generated abstracts was predominately attributed to the presence of unrealistic data/values. The primary reason for misidentifying original abstracts as AI was attributed to writing style. Conclusions Experienced reviewers faced difficulties in distinguishing between human and AI‐generated research content within shoulder and elbow surgery. The presence of unrealistic data facilitated correct identification of AI abstracts, whereas misidentification of original abstracts was often ascribed to writing style. Clinical Relevance With rapidly increasing AI advancements, it is paramount that ethical standards of scientific reporting are upheld. It is therefore helpful to understand the ability of reviewers to identify AI‐generated content.
Trends and Disparities in Valvular Heart Disease Mortality in the United States From 1999 to 2020
Tan, Min Choon , Yeo, Yong Hao , San, Boon Jian , Suleiman, Addi, Lee, Justin Z. , Chatterjee, Arka , Sell‐Dottin, Kristen , Sweeney, John P., Fortuin, F. David , Lee, Kwan , Sell-Dottin, Kristen A , Lee, Kwan S , Yeo, Yong Hao , Fortuin, Floyd David , Tan, Min C

Mayo Clinic

Journal of the American Heart Association | April 8, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.030895 | PMID 38587138 Get It

Background Percutaneous heart valve procedures have been increasingly performed over the past decade, yet real‐world mortality data on valvular heart disease (VHD) in the United States remain limited. Methods and Results We queried the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research database among patients ≥15 years old from 1999 to 2020. VHD and its subtypes were listed as the underlying cause of death. We calculated age‐adjusted mortality rate (AAMR) per 100 000 individuals and determined overall trends by estimating the average annual percent change using the Joinpoint regression program. Subgroup analyses were performed based on demographic and geographic factors. In the 22‐year study, there were 446 096 VHD deaths, accounting for 0.80% of all‐cause mortality (56 014 102 people) and 2.38% of the total cardiovascular mortality (18 759 451 people). Aortic stenosis recorded the highest mortality of VHD‐related death in both male (109 529, 61.74%) and female (166 930, 62.13%) populations. The AAMR of VHD has declined from 8.4 (95% CI, 8.2–8.5) to 6.6 (95% CI, 6.5–6.7) per 100 000 population. Similar decreasing AAMR trends were also seen for the VHD subtypes. Men recorded higher AAMR for aortic stenosis and aortic regurgitation, whereas women had higher AAMR for mitral stenosis and mitral regurgitation. Mitral regurgitation had the highest change in average annual percent change in AAMR. Conclusions The mortality rate of VHD among the US population has declined over the past 2 decades. This highlights the likely efficacy of increasing surveillance and advancement in the management of VHD, resulting in improved outcomes.
Deep and Repeated Response to Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2–Amplified Large-Cell Neuroendocrine Carcinoma With Brain Metastases: A Case Report
Algarin-Perneth, Sandra , Suleiman, Riham , Abeykoon, Jithma P. , Hálfdánarson, Þorvarður R. , Yi, Joanne, Peikert, Tobias, McGarrah, Patrick W. , Halfdanarson, Thorvardur R , Fuentes-Bayne, Harry E, Yi, Joanne E, McGarrah, Patrick , Fuentes, Harry E

Mayo Clinic

JCO Precision Oncology | October 26, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.23.00242 | PMID 37883722 Get It

Metastatic CUP is complex, especially NCUP. Precision oncology is crucial for rare, aggressive cancers. A 54-year-old had HER2+ neuroendocrine carcinoma of unknown origin. T-DXd treatment, response, re-challenge show importance of genomics and caution.
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate‐to‐Severe Osteoarthritis or Ad
Goodman, Susan M. , Yates, Adolph J. , Baker, Joshua F. , Bass, Phyllis, Bekele, Delamo I. , Dass, Danielle, Jevsevar, David S. , Suleiman, Linda I. , Wolfstadt, Jesse , Bartosiak, Kimberly , Cohen‐Rosenblum, Anna , Courtney, P. Maxwell , Ghosh, Nilasha , Mehta, Bella , Rana, Adam J. , Sullivan, Nancy , Turgunbaev, Marat, Wysham, Katherine D. , Yip, Kevin , Yue, Linda, Zywiel, Michael G. , Russell, Linda , Turner, Amy S. , Goodman, Susan M , Baker, Joshua F , Bekele, Delamo , Ghomrawi, Hassan M K , Kwoh, Chian Kent , Bedard, Nicholas A. , Ghosh, Nilasha , King, Lauren K , Meara, Alexa Simon , Wysham, Katherine D , Turner, Amy S , Hannon, Charles P. , Austin, Matthew S. , Guyatt, Gordon , Aggarwal, Vinay Kumar , Ghomrawi, Hassan , Lajam, Claudette M. , Meng, Charis F. , Moreland, Larry W. , Blevins, Jason L. , Fernandez‐Ruiz, Ruth , Gausden, Elizabeth B. , Mirza, Reza Donald , Singh, Jasvinder A.

Mayo Clinic

Arthritis & Rheumatology | September 25, 2023 | Volume: 75 | Issue: 11 | Pages: 1877-1888

10.1002/art.42630 | PMID 37746897 Get It

ObjectiveTo develop evidence‐based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient‐important outcomes including, but not limited to, pain, function, infection, hospitalization, and death at 1 year for patients with symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis of the hip or knee who have previously attempted nonoperative therapy, and for whom nonoperative therapy was ineffective, and who have chosen to undergo elective hip or knee arthroplasty (collectively referred to as TJA).MethodsWe developed 13 clinically relevant population, intervention, comparator, outcomes (PICO) questions. After a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of evidence (high, moderate, low, or very low), and evidence tables were created. A Voting Panel, including 13 physicians and patients, discussed the PICO questions until consensus was achieved on the direction (for/against) and strength (strong/conditional) of the recommendations.ResultsThe panel conditionally recommended against delaying TJA to pursue additional nonoperative treatment including physical therapy, nonsteroidal antiinflammatory drugs, ambulatory aids, and intraarticular injections. It conditionally recommended delaying TJA for nicotine reduction or cessation. The panel conditionally recommended delay for better glycemic control for patients who have diabetes mellitus, although no specific measure or level was identified. There was consensus that obesity by itself was not a reason for delay, but that weight loss should be strongly encouraged, and the increase in operative risk should be discussed. The panel conditionally recommended against delay in patients who have severe deformity or bone loss, or in patients who have a neuropathic joint. Evidence for all recommendations was graded as low or very low quality.ConclusionThis guideline provides evidence‐based recommendations regarding the optimal timing of TJA in patients who have symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis for whom nonoperative therapy was ineffective to improve patient‐important outcomes, including pain, function, infection, hospitalization, and death at 1 year. We acknowledge that the evidence is of low quality primarily due to indirectness and hope future research will allow for further refinement of the recommendations.
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate‐to‐Severe Osteoarthritis or Ad
Goodman, Susan M. , Yates, Adolph J. , Baker, Joshua F. , Bass, Phyllis, Bekele, Delamo I. , Dass, Danielle, Jevsevar, David S. , Suleiman, Linda I. , Wolfstadt, Jesse , Bartosiak, Kimberly , Cohen‐Rosenblum, Anna , Courtney, P. Maxwell , Ghosh, Nilasha , Mehta, Bella , Rana, Adam J. , Sullivan, Nancy , Turgunbaev, Marat, Wysham, Katherine D. , Yip, Kevin , Yue, Linda, Zywiel, Michael G. , Russell, Linda , Turner, Amy S. , Goodman, Susan M , Baker, Joshua F , Bekele, Delamo , Ghomrawi, Hassan M K , Kwoh, Chian Kent , Bedard, Nicholas A. , Ghosh, Nilasha , King, Lauren K , Meara, Alexa Simon , Wysham, Katherine D , Turner, Amy S , Hannon, Charles P. , Austin, Matthew S. , Guyatt, Gordon , Aggarwal, Vinay Kumar , Dass, Danielle, Ghomrawi, Hassan , Lajam, Claudette M. , Meng, Charis F. , Moreland, Larry W. , Blevins, Jason L. , Fernandez‐Ruiz, Ruth , Gausden, Elizabeth B. , Mirza, Reza Donald , Singh, Jasvinder A.

Mayo Clinic

Arthritis Care & Research | September 25, 2023 | Volume: 75 | Issue: 11 | Pages: 2227-2238

10.1002/acr.25175 | PMID 37743767 Get It

ObjectiveTo develop evidence‐based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient‐important outcomes including, but not limited to, pain, function, infection, hospitalization, and death at 1 year for patients with symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis of the hip or knee who have previously attempted nonoperative therapy, and for whom nonoperative therapy was ineffective, and who have chosen to undergo elective hip or knee arthroplasty (collectively referred to as TJA).MethodsWe developed 13 clinically relevant population, intervention, comparator, outcomes (PICO) questions. After a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of evidence (high, moderate, low, or very low), and evidence tables were created. A Voting Panel, including 13 physicians and patients, discussed the PICO questions until consensus was achieved on the direction (for/against) and strength (strong/conditional) of the recommendations.ResultsThe panel conditionally recommended against delaying TJA to pursue additional nonoperative treatment including physical therapy, nonsteroidal antiinflammatory drugs, ambulatory aids, and intraarticular injections. It conditionally recommended delaying TJA for nicotine reduction or cessation. The panel conditionally recommended delay for better glycemic control for patients who have diabetes mellitus, although no specific measure or level was identified. There was consensus that obesity by itself was not a reason for delay, but that weight loss should be strongly encouraged, and the increase in operative risk should be discussed. The panel conditionally recommended against delay in patients who have severe deformity or bone loss, or in patients who have a neuropathic joint. Evidence for all recommendations was graded as low or very low quality.ConclusionThis guideline provides evidence‐based recommendations regarding the optimal timing of TJA in patients who have symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis for whom nonoperative therapy was ineffective to improve patient‐important outcomes, including pain, function, infection, hospitalization, and death at 1 year. We acknowledge that the evidence is of low quality primarily due to indirectness and hope future research will allow for further refinement of the recommendations.
Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience.
Duran, Mayra, Suleiman, Riham , Perneth, Sandra Algarin, Torres, Ricardo Loor, Jacome, Cristian Soto , Thomé, Stephan D. , Leon‐Ferre, Roberto A. , Bayne, Harry E. Fuentes, Gile, Jennifer , Graham, Rondell P. , Villasboas, José C. , Hálfdánarson, Þorvarður R.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e18807-e18807

10.1200/jco.2023.41.16_suppl.e18807 Get It

e18807 Background: CUP represents both a diagnostic and a management challenge. Despite improvements through sophisticated imaging modalities, specific and sensitive testing using immunohistochemistry, a concrete determination of the site of origin of the primary tumor can still be a diagnostic challenge Hereby, we described the genomic landscape of patients with CUP treated at our institution. Methods: Retrospective study of patients with CUP treated at Mayo Clinic Rochester MN from 2010 to 2021. Next generation sequencing (NGS) information was abstracted, and alterations were ranked into different levels of actionability following the Onco KB framework. All data were analyzed by the SPSS version 22.0 software (SPSS, Chicago, IL, United States). Results: From a total of 214 patients, we identified 67 (32%) patients in whom NGS was performed. Among patients with available NGS the median age was 64 years (range: 35-86) and 51% were female. the most prevalent histology included adenocarcinoma (39%), carcinoma NOS (31%), and neuroendocrine tumors (12%). NGS on tumor (t-NGS) was available in 56 (84 %) patients, circulating tumor NGS (b-NGS) was available in 12 (18%) patients, and only 1 patient had both testing available. Among the 56 patients with available t-NGS, MSI-high was detected in 9 patients, whereas among the 12 patients with available b-NGS, MSI-high was detected in 8 patients; yielding an MSI-high detection rate of 16% and 67% for t-NGS and b-NGS. In this cohort, there were a total of 474 genomic alterations detected from which 103 (22 %) were able to be ranked into one therapeutic level following the OncoKB framework. Genomic alterations were most observed among patients with carcinoma (n = 50, 48.53%) adenocarcinoma (n = 33, 32.03 %), squamous cell carcinoma (n = 3, 2.91 %) and neuroendocrine tumor (n = 2, 1.94%). Following the OncoKB framework, 39-level 1 genomic alterations were detected in a total of 14 genes. The most common level 1 genomic alterations comprised the BRCA2 (20.51%), NF1 ATM (17.95%) and HER2/NEU (ERBB2) (15.38%) genes. Therapeutic level 2 included 51 genomic alterations in 13 genes of which KRAS (17.65%), BRAF (15.69%), and BRCA2 (15.69%) were the most prevalent mutated genes. Additionally, level R comprised 13 genomic alterations in the following genes: KRAS (69.23) NRAS (23.08%) and PDGFRA (7.69%). Conclusions: CUP are malignancies rich in potentially actionable alterations, and NGS of tissue and blood samples can inform systemic therapy decisions. Alteration-specific targeted therapy may be an option for a substantial proportion of patients. NGS of tumor tissue or blood should be considered for all patients with CUP.
Clinicopathological features and treatment patterns of patients with cancer of unknown primary site (CUP): Mayo Clinic experience.
Perneth, Sandra Algarin, Suleiman, Riham , Duran, M., Torres, Ricardo Loor, Jacome, Cristian Soto , Leon‐Ferre, Roberto A. , Thomé, Stephan D. , Bayne, Harry E. Fuentes, Gile, Jennifer , Villasboas, José C. , Graham, Rondell P. , Hálfdánarson, Þorvarður R.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e18803-e18803

10.1200/jco.2023.41.16_suppl.e18803 Get It

e18803 Background: CUPs are a heterogeneous group of metastatic cancers for which a standardized diagnostic work-up fails to identify the site of origin at the time of diagnosis. CUP accounts for 3%-5% of all cancer diagnoses worldwide, and the natural history of patient with CUP differs from that of patients (pts) with cancer with known primary tumor. Here we report and summarize the clinical features of patients with CUP treated at Mayo Clinic. Methods: Retrospective study of patients treated at Mayo Clinic Rochester MN from 2010 to 2021. Patient demographics, tumor-related variables, treatment-related variables, and clinical data were extracted. Descriptive statistics were used, and all data were analyzed by the SPSS version 22.0 software (SPSS, Chicago, IL, United States). Results: From a total of 214 pts, 207 pts were included, as primary tumor site was identified in 7 patients after initial evaluation. The pts in this study were predominantly white (87%) of female (50.2%) gender with a mean age of 63 (SD: 13) without history of smoking (51%) and either private or public insurance (82.6%). The predominant histology was adenocarcinoma (30%), followed by neuroendocrine neoplasms (27%), and carcinoma NOS (not otherwise specified) (25%). The most prevalent grade in this cohort was grade III with poorly differentiated tumor cells. All pts had diagnostic imaging and the most used imaging modalities included CT (81.2%), and PET-CT (43.5%). In our cohort, the 3 most common sites of metastases included lymph nodes (57.5%), liver (37.8%), lung (34.3%), and bone (23.7%); and in 64% of pts, there was a specific presentation pattern including liver-predominant (24.6%), lymph node-predominant (24.6%), bone-predominant (7.7%), and peritoneal carcinomatosis (7.7%). The majority of pts received systemic therapy (69%) as first line of therapy and the most frequent first line regimens included platinum-doublet (26.5%), gemcitabine-based regimen (20.7%), 5FU-based regimens (18%) and somatostatin analogs (16.7%); whereas salvage radiation and ablation were offered to 11% of pts and surgery to 17%. The median follow-up time was 22 months (IQR: 45) with a median survival time of 23 months and the 3-year cumulative survival rate was 30%. Conclusions: The heterogenous nature of CUPs and lack of specific immunohistochemical signature prevents primary tissue of origin diagnoses in CUP pts. Without the identification of a primary origin site, treatment is restricted to generic chemotherapy with limited benefit as demonstrated in this cohort.
Survival in patients with cancer of unknown primary site (CUP): Mayo Clinic experience.
Suleiman, Riham , Duran, Mayra, Perneth, Sandra Algarin, Torres, Ricardo Loor, Jacome, Cristian Soto , Leon‐Ferre, Roberto A. , Thomé, Stephan D. , Bayne, Harry E. Fuentes, Gile, Jennifer , Graham, Rondell P. , Villasboas, José C. , Hálfdánarson, Þorvarður R.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e18802-e18802

10.1200/jco.2023.41.16_suppl.e18802 Get It

e18802 Background: CUP is a rare cancer with an incidence of 7–12 cases per 100,000/year. CUP is defined as metastatic cancer with no identifiable primary tumor despite comprehensive evaluation. Despite its heterogeneous clinicopathological presentation, the treatment of CUP has primarily been with platinum-based combination chemotherapies but results are poor and survival is short. Here, we describe survival outcomes in real-world dataset of patients with CUP seen at a tertiary referral center. Methods: Retrospective study of patients treated at Mayo Clinic, Rochester MN, from 2010 to 2021. Survival probabilities were estimated with the Kaplan-Meier method. We used Cox proportional hazard regression with forward modeling to explore the association between each variable and death. Overall survival (OS) analysis was conducted in the entire cohort, and it was stratified by histological subtype. For the hypothesis test, we considered p < 0.05 to be statistically significant; all tests were two-sided. All data were analyzed by the SPSS version 22.0 software (SPSS, Chicago, IL, United States). Results: From a total of 214 patients, 198 patients were included in the survival analysis. The patients were predominantly white (87%), female (50.2%), with a mean age of 63 (SD: 13) without history of smoking (51%). The predominant histology was adenocarcinoma (30%), followed by neuroendocrine neoplasms (NEN) (27%), carcinoma NOS (25%), squamous cell carcinoma (SCC) (10%) and non-classifiable tumors (7%). The median follow-up time was 23 months, and medial OS was 23 months in the entire cohort. OS by histology was as follows: 51 months for NEN, 34 months for SCC, 18 months for carcinomas NOS and 11 months for adenocarcinomas (p < 0.001) (fig.1). Similar OS trends were observed when we restricted the analysis to poorly differentiated tumors. The 3- and 5-year cumulative survival by histology were as follows: 7% and 0% for adenocarcinoma, 25% and 8% for carcinoma NOS, 39% and 17% for SCC, and 56% and 22% for NEN. In Cox regression models we did not identify any prognostic factors among patients with adenocarcinoma. Conclusions: Patients with adenocarcinoma of unknown primary possess a considerable challenge and the OS is short. CUP of other histologies have higher OS. This study highlights the need of accurate tumor identification and better treatment, perhaps as a multiomics therapeutic approach.